LianBio (LIANY)
OTCMKTS · Delayed Price · Currency is USD
0.294
0.00 (-0.03%)
Sep 27, 2024, 4:00 PM EDT

LianBio Company Description

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries.

The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn’s disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.

It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy.

The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

LianBio
Country Cayman Islands
Founded 2019
Industry Biotechnology
Sector Healthcare
Employees 163
CEO Adam Stone

Contact Details

Address:
103 Carnegie Center Drive
Princeton, 08540
United States
Phone 609 486 2308
Website lianbio.com

Stock Details

Ticker Symbol LIANY
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
ISIN Number US53000N1081
SIC Code 2836

Key Executives

Name Position
Adam Leo Stone Interim Chief Executive Officer and Director
Konstantin Poukalov Founder and Executive Chairman
Ehong Gu Interim Chief Financial Officer, Vice President and Head of Global Finance
Ji Chen Senior Vice President and General Counsel
Brianne Jahn Chief Business Officer
Levvy Lv D. Eng Senior Vice President and Global Head of Development